Brief: Xspray Q3 Revenue SEK 0
06/11/2024 07:00
Nov 06 (Reuters) - Xspray Q3 adjusted EPS SEK -2.44. * Q3 adjusted free cash flow SEK -41.275 million * Q3 pretax profit SEK -82.272 million
Recent news on Xspray Pharma publ AB
See all newsBrief: Xspray Pharma Gets CRL From FDA
Sweden's Xspray Q1 loss narrows, upbeat on Dasynoc prospects
Brief: Xspray Pharma Q1 Pretax Loss SEK 35.4 Mln
Brief: Xspray Pharma To Receive About SEK 113 Million From Rights, Over-Allotment Issues
Brief: FDA Accepts Trade Name Nilopki For Xspray's Drug Candidate XS003